Skip to content
10-Q

Quarterly Report

ARRAY BIOPHARMA INC

0001100412-19-000021

← back to feed
Filed
May 7, 2019 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2019 · Apr 26, 2019 221.75M sh
Shares Diluted Q3 2019 · Mar 31, 2019 219.91M sh
Shares Diluted Q3 2019 · Mar 31, 2019 215.96M sh
Shares Diluted Q3 2019 · Mar 31, 2018 208.99M sh
Shares Diluted Q3 2019 · Mar 31, 2018 194.43M sh
Capex Q3 2019 · Mar 31, 2019 $1.46M
Capex Q3 2019 · Mar 31, 2018 $1.12M
Operating Cash Flow Q3 2019 · Mar 31, 2019 −$87.43M
Operating Cash Flow Q3 2019 · Mar 31, 2018 −$91.15M
Long Term Debt Q3 2019 · Mar 31, 2019 $134.25M
Long Term Debt Q3 2019 · Jun 30, 2018 $93.38M
Short Term Debt Q3 2019 · Mar 31, 2019 $0
Short Term Debt Q3 2019 · Jun 30, 2018 $15.9M
Cash And Equivalents Q3 2019 · Mar 31, 2019 $96.64M
Cash And Equivalents Q3 2019 · Jun 30, 2018 $114.75M
Stockholders Equity Q3 2019 · Mar 31, 2019 $301.63M
Stockholders Equity Q3 2019 · Dec 31, 2018 $285.35M
Stockholders Equity Q3 2019 · Jun 30, 2018 $219.74M
Stockholders Equity Q3 2019 · Mar 31, 2018 $265.15M
Stockholders Equity Q3 2019 · Dec 31, 2017 $242.18M
Stockholders Equity Q3 2019 · Jun 30, 2017 $11.73M
Current Liabilities Q3 2019 · Mar 31, 2019 $86.66M
Current Liabilities Q3 2019 · Jun 30, 2018 $95.93M
Total Liabilities Q3 2019 · Mar 31, 2019 $265.38M
Total Liabilities Q3 2019 · Jun 30, 2018 $240.62M
Current Assets Q3 2019 · Mar 31, 2019 $493.91M
Current Assets Q3 2019 · Jun 30, 2018 $451.54M
Total Assets Q3 2019 · Mar 31, 2019 $567M
Total Assets Q3 2019 · Jun 30, 2018 $460.36M
Eps Diluted Q3 2019 · Mar 31, 2019 −$0.17
Eps Diluted Q3 2019 · Mar 31, 2019 −$0.34
Eps Diluted Q3 2019 · Mar 31, 2018 −$0.11
Eps Diluted Q3 2019 · Mar 31, 2018 −$0.49
Eps Basic Q3 2019 · Mar 31, 2019 −$0.17
Eps Basic Q3 2019 · Mar 31, 2019 −$0.34
Eps Basic Q3 2019 · Mar 31, 2018 −$0.11
Eps Basic Q3 2019 · Mar 31, 2018 −$0.49
Sga Expense Q3 2019 · Mar 31, 2019 $35.55M
Sga Expense Q3 2019 · Mar 31, 2019 $90.91M
Sga Expense Q3 2019 · Mar 31, 2018 $16.77M
Sga Expense Q3 2019 · Mar 31, 2018 $40.43M
Rd Expense Q3 2019 · Mar 31, 2019 $65.54M
Rd Expense Q3 2019 · Mar 31, 2019 $183.21M
Rd Expense restated Q3 2019 · Mar 31, 2018 $71.35M
Rd Expense restated Q3 2019 · Mar 31, 2018 $180.88M
Net Income Q3 2019 · Mar 31, 2019 −$37.49M
Net Income Q3 2019 · Mar 31, 2019 −$73.67M
Net Income Q3 2019 · Mar 31, 2018 −$22.85M
Net Income Q3 2019 · Mar 31, 2018 −$94.9M
Operating Income Q3 2019 · Mar 31, 2019 −$37.45M
Operating Income Q3 2019 · Mar 31, 2019 −$72.01M
Operating Income Q3 2019 · Mar 31, 2018 −$21.75M
Operating Income Q3 2019 · Mar 31, 2018 −$82.98M